Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...
A medical expert claims Trump's bruised hand proves he is receiving monthly infusions for possible dementia, linking it to ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
Eisai and partner BioArctic recently reported at the CTAD 2025 conference that long-term data for Leqembi (lecanemab) suggest early, continued treatment can substantially delay progression from mild ...
Amid health speculations, US President Donald Trump confidently talks about his 'good memory' during the Kennedy Centre ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called ...
Pharmaceutical Technology on MSN
Eisai seeks PMDA approval for subcutaneous Leqembi in Japan
If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback